Compare American Homes 4 Rent Class A (AMH) vs Amylx Pharmaceuticals Inc (AMLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Homes 4 Rent Class A vs Amylx Pharmaceuticals Inc — how do they compare? American Homes 4 Rent Class A trades at $33.78 (market cap $12.28B), while Amylx Pharmaceuticals Inc trades at $23.55 (market cap $2.64B). The key difference: American Homes 4 Rent Class A is far larger — about 4.7× Amylx Pharmaceuticals Inc's market cap, and American Homes 4 Rent Class A pays a 3.87% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMH | AMLX | |
|---|---|---|
Market Cap | $12.28B | $2.64B |
Sector | Real Estate | Health |
52-Week High | $35.82 | $24.19 |
52-Week Low | $27.38 | $7.82 |
Enterprise Value | $17.35B | $2.39B |
Dividend Yield | 3.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMH trades at $33.73, down 1.17% today, with a bullish technical signal and strong fundamental performance. The company reported Q2 2026 FFO of $0.49 per share, beating estimates, and raised full-year guidance. Revenue growth is steady, with net income margin improving to 25.53% in 2026. Analysts maintain a Moderate Buy consensus with a $36.45 price target, indicating potential upside from current levels.
Outlook is positive due to consistent earnings beats and robust rental demand, but risks include high debt levels and regulatory changes affecting institutional home buying. The stock offers value with a P/E of 27.09 and dividend yield support, though investors should monitor interest rate sensitivity and housing market volatility.
AMLX trades at $23.61, up 4.15% today, with strong analyst support (91% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics (ROE -74.73%, ROA -66.25%). Recent Q2 2026 earnings missed expectations, but the company maintains $250.8M cash runway into 2028, supporting its pivotal Phase 3 LUCIDITY trial readout expected August-September 2026.
The investment thesis hinges on successful avexitide clinical outcomes, with potential 2027 launch offering significant upside. Key risks include ongoing financial losses, clinical trial execution, and competitive pressures. Current valuation at 11.02x book value appears stretched given negative earnings, making positive trial results critical for justifying premium pricing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Homes 4 Rent Class A
American Homes 4 Rent is a real estate investment trust primarily focused on acquiring, operating, and leasing single-family homes as rental properties throughout the United States. The company's real estate portfolio is largely comprised of single-family properties in urban markets in the Southern and Midwestern regions of the U.S. American Homes 4 Rent's land holdings also represent a sizable percentage of its total assets in terms of value. The company derives the vast majority of its income in the form of rental revenue from single-family properties through short-term or annual leases. The firm's largest geographical markets include Dallas, Texas
Read more on AMH →About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →
